ArticleFrontiers in aging neuroscience2025
Brain structural MRI marker for predicting conversion to Parkinson's disease in individuals with prodromal symptoms.
Article in Frontiers in aging neuroscience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: During the prodromal stage of Parkinson's disease (PD), brain structural alterations precede clinical diagnosis and offer opportunities for early detection. We investigated whether combining clinical non-motor markers with an MRI-based brain structural marker could enhance predictive performance for PD conversion. Methods: Individuals with prodromal symptoms ( Results: Six individuals converted to PD within 4 years. The MRI marker classified 21 individuals as having PD-like brain patterns, including all six converters. When combined with olfactory dysfunction, the approach achieved optimal performance with 100% sensitivity, 80% specificity, and 90% balanced accuracy, outperforming individual markers and other combinations. Conclusion: MRI-quantified brain structural similarity to PD, particularly when combined with olfactory assessment, significantly enhances prediction of PD conversion in individuals with prodromal symptoms. This accessible, multimodal approach could facilitate early identification of high-risk individuals for targeted interventions and clinical trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.